|

Imzokitug Clinical Trials

2 actively recruiting trials across 2 locations

▲ +1 trial since July 2026

Also known as: Anti-CCR8, Anti-CCR8 Monoclonal Antibody BMS-986340, BMS 986340, BMS-986340, BMS986340

Pipeline

Phase 2: 2

Top Sponsors

  • Mayo Clinic1
  • Bristol-Myers Squibb1

Indications

  • Cancer2
  • Locally Advanced Non-Small Cell Lung Cancer (NSCLC)1
  • Recurrent Pancreatic Adenocarcinoma1
  • Metastatic Non-small Cell Lung Cancer (NSCLC)1
  • Metastatic Pancreatic Adenocarcinoma1

Scottsdale, Arizona1 trial

BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma

Mayo Clinic in Arizona

Phase 2

Athens, Georgia1 trial

A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Local Institution - 0170

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.